Navigation Links
Poniard Pharmaceuticals Announces $6.5 Million Financing
Date:12/22/2009

hat are resistant to existing platinum-based cancer therapies. Clinical studies to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Poniard has completed a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of patients with small cell lung cancer. The Company is also conducting separate Phase 2 trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant (hormone-refractory) prostate cancer. Additionally, Poniard has completed a Phase 1 cardiac safety trial of picoplatin and a Phase 1 study evaluating the oral formulation of picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements, including statements about the Company's financial condition and prospects, the sufficiency of current capital resources and the planned use of capital.. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the Company's anticipated operating losses and need for future capital; the risk that future financing alternatives may not be available on favorable terms or at all, the potential safety and efficacy of the Company's picoplatin product candidates; the receipt and timing of any FDA and other required regulatory approvals, if any; if regulatory approval of any product candidate is received, the market's acceptance of that product or the occurrence post-approval problems that ma
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 GEA Niro Soavi the ... laboratory homogenizer, the PandaPLUS 2000, which is ideal for ... and cell disruption . This compact laboratory homogenizer ... juices, liquid food, food additives and ingredients as well ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... January 22, 2015 Selexis SA, a ... Research Cell Banks (RCBs) used for drug discovery to ... Banks will include Next-Generation Sequencing (NGS) data ... de-risks biologic manufacturing by ensuring the integrity of the ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2
... Feb. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC ... filed a New Drug Application (NDA) with the U.S. ... therapeutic Onrigin (laromustine) Injection as a single agent for ... or older with de novo poor-risk acute ...
... Feb. 17 GeneGo, Inc., the leading systems ... licensed 250 manually curated pathway maps from GeneGo, ... Available at www.millipore.com/pathways , the tool links ... well as relevant bioinformatics content to related biological ...
... - Sales Grow by 10.7% to EUR1.06bn, - Adjusted ... EUR1.83, - Adjusted EBITDA Margin Rises From 19.0 to 19.5%, ... Gerresheimer, again considers itself well equipped to meet the ... substantial sales growth of 6% to 7% in, the ...
Cached Biology Technology:Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 2Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 3Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 4Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 2Millipore Launches an Interactive Biological Pathway Tool Using GeneGo's Manually Curated Pathway Maps 3Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 2Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 3Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 4
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced ... Perimeter Security Systems Market" report to their offering. ... American perimeter security market is estimated to grow at a ... market holds a larger share in this market, ...
(Date:12/19/2014)... LaunchKey , the first decentralized mobile authentication and authorization ... era, today announced the close of $3 million in ... Metamorphic Ventures with participation from ENIAC Ventures, Crosslink Capital, ... has raised $4 million to date, and will use ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 The Defense ... easier to detect and prevent counterfeit microcircuits from entering ... started performing an in-house microcircuit anti-counterfeit initiative dubbed DNA ... microcircuits while increasing their reliability throughout the supply chain. ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... researchers from the University of Maryland Center for Environmental ... to forecast the effects of environmental change on the ... a $620,000 grant from the National Science Foundation, will ... near Alexandria, Virginia. "Freshwater marshes are integral to ...
... Commonwealth University researchers have identified the role of a ... development, which may one day help shed light on ... The steps involved with conception and pregnancy are ... In females, fertility is dependant on the growth of ...
... year of a project to improve predictions of toxic ... part of an evolving national ecological forecasting capability. NOAA ... regional project over the next four years. The project ... Harmful Algal Blooms, or ECOHAB, program. Funded partners ...
Cached Biology News:Researchers identify gene with possible link to infertility in mice 2NOAA awards funds to improve toxic algal bloom predictions in the Western Gulf of Mexico 2
BD IMagnet 1 each...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
... active MW: 34.2kDa Formulation: 10mM HEPES, ... 1mM dithiothreitiol with 50% glycerol Properites: ... the Certificate of Analysis for individual ... precipitation followed by gel filtration and ...
Supplemental reagent for annexin V assay....
Biology Products: